AI medical solution company AIDOT Co., Ltd. (CEO Jaehoon Jeong) announced that it received “Excellent” ratings in the final evaluations for three national and local government support projects related to its three AI solutions—Cerviray AI, ECHO dot AI, and URO dot AI. Based on real-world evidence secured through field validation and clinical evaluations, the company plans to accelerate market expansion and follow-up commercialization efforts.

An “Excellent” rating signifies that the company has successfully connected government-funded projects to actual business outcomes and has fully met both qualitative and quantitative evaluation criteria, thereby strengthening its export capabilities and commercialization efforts with funding supported by taxpayers.

AIDOT carried out local field validation for Cerviray AI (an AI-assisted system for cervical cancer diagnosis) and a global certification project for ECHO dot AI (an AI-assisted system for otitis media diagnosis) under the “2025 Gangwon AI Healthcare Company Development Support Program.” In addition, under the “2025 Domestic Medical Device User (Medical Institution) Evaluation Support Program,” the company conducted a multi-center evaluation of URO dot AI (AI-assisted software for urinary stone diagnosis).

Evaluation comments on the project outcomes noted that “the potential for future use in the AI healthcare field is high.”

For the global certification and local validation projects, quantitative performance results met planned targets, and additional achievements such as technology advancement were also mentioned positively.

Reviewers also stated that the support programs contributed to technological progress and the promotion of overseas sales, and the overall assessment described AIDOT as an “excellent executing institution that carried out the project faithfully and effectively.”

By product, Cerviray AI conducted local field validation at a hospital in Indonesia, examining its applicability to the local medical environment and operational processes.

ECHO dot AI advanced preparations for international expansion by progressing with certification readiness aligned with FDA 510(k) and CE MDR requirements.

URO dot AI underwent a multi-center evaluation at domestic medical institutions to review its usability in clinical settings. The evaluation confirmed that applying AI-assisted reading reduced the average interpretation time from 70 seconds to 25 seconds (a 64.49% decrease).

The company stated that, leveraging the evidence and on-site references obtained through validation and clinical evaluations, it will expand adoption in domestic healthcare settings while advancing preparations for overseas entry, accelerating commercialization.

Key features of Cerviray AI include:

• On-device AI interpretation (no internet required, results provided immediately)

• A Class III AI medical device approval by Korea’s Ministry of Food and Drug Safety (MFDS)

• Lesion classification output (CIN1 / CIN2–3 / CIN3+)

• Display of detailed lesion detection boxes

Korea Economic TV / 2026-01-21 / Jaehjoon Yang, Deputy Director